Literature DB >> 8913839

Purity determinations in the bulk drug of the novel indoloquinone antitumor agent EO9.

J D Jonkman-de Vries1, J J Kettenes-van den Bosch, R E Henrar, A Bult, J H Beijnen.   

Abstract

The pharmaceutical development of the investigational cytotoxic drug EO9 included the structural characterization of the bulk drug by nuclear magnetic resonance (NMR) spectroscopy, mass spectrometry (MS) and infrared (IR) spectroscopy, and analytical characterization by high-performance liquid chromatography and ultraviolet/visible spectrophotometry. The presence of impurities in the bulk drug was investigated. The intermediates in the synthesis of EO9 were structurally characterized by NMR spectroscopy and MS, and analytically characterized by HPLC analysis with photodiode array (PDA) detection. All of the intermediates were below their limits of detection in EO9 bulk drug. The amounts of residual organic solvents were determined by gas chromatography. Methanol and ethanol were detected, but the amounts present did not exceed the limits as set in the United States Pharmacopeia XXII.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8913839     DOI: 10.1007/bf00210789

Source DB:  PubMed          Journal:  Invest New Drugs        ISSN: 0167-6997            Impact factor:   3.850


  8 in total

1.  Survey of chlorinated hydrocarbons and other organic volatile impurities in captopril raw materials and tablets.

Authors:  T D Cyr; R C Lawrence; E G Lovering
Journal:  Pharm Res       Date:  1992-09       Impact factor: 4.200

2.  Structure and stereochemistry of some 1,2-disubstituted mitosenes from solvolysis of mitomycin C and mitomycin A.

Authors:  W G Taylor; W A Remers
Journal:  J Med Chem       Date:  1975-03       Impact factor: 7.446

3.  EORTC/CRC/NCI guidelines for the formulation of investigational cytotoxic drugs.

Authors:  J P Davignon; J A Slack; J H Beijnen; W R Vezin; T J Schoemaker
Journal:  Eur J Cancer Clin Oncol       Date:  1988-09

4.  Mitomycin antitumour agents: a review of their physico-chemical and analytical properties and stability.

Authors:  J H Beijnen; H Lingeman; H A Van Munster; W J Underberg
Journal:  J Pharm Biomed Anal       Date:  1986       Impact factor: 3.935

5.  EO9: a novel bioreductive alkylating indoloquinone with preferential solid tumour activity and lack of bone marrow toxicity in preclinical models.

Authors:  H R Hendriks; P E Pizao; D P Berger; K L Kooistra; M C Bibby; E Boven; H C Dreef-van der Meulen; R E Henrar; H H Fiebig; J A Double
Journal:  Eur J Cancer       Date:  1993       Impact factor: 9.162

6.  Structure-activity relationships for DT-diaphorase reduction of hypoxic cell directed agents: indoloquinones and diaziridinyl benzoquinones.

Authors:  S M Bailey; N Suggett; M I Walton; P Workman
Journal:  Int J Radiat Oncol Biol Phys       Date:  1992       Impact factor: 7.038

7.  DT-diaphorase activity correlates with sensitivity to the indoloquinone EO9 in mouse and human colon carcinomas.

Authors:  M I Walton; M C Bibby; J A Double; J A Plumb; P Workman
Journal:  Eur J Cancer       Date:  1992       Impact factor: 9.162

8.  The sensitivity of human tumour cells to quinone bioreductive drugs: what role for DT-diaphorase?

Authors:  N Robertson; I J Stratford; S Houlbrook; J Carmichael; G E Adams
Journal:  Biochem Pharmacol       Date:  1992-08-04       Impact factor: 5.858

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.